Myriad Genetics ( (MYGN) ) has released its Q3 earnings. Here is a breakdown of the information Myriad Genetics presented to its investors.

Myriad Genetics Inc (MYGN) reports robust revenue growth and strategic initiatives despite facing policy changes impacting ...

Investigation Details On October 31, 2024, it was revealed that UnitedHealth Group (“UnitedHealth”) would no longer cover GeneSight, Myriad’s genetic test to help determine which mental health ...

In a report released yesterday, Daniel Brennan from TD Cowen maintained a Hold rating on Myriad Genetics (MYGN – Research Report), with a ...

Myriad Genetics said it is in talks with UnitedHealthcare to ensure that enrollees continue to have access to its GeneSight mental health medication test after the insurer changed its coverage policy.

SALT LAKE CITY, Nov. 04, 2024 (GLOBE NEWSWIRE) -- , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, was ...

The catalogue of genetic factors that have been implicated in kidney disease continues to grow. In this guide to gene–disease relationships, the authors discuss the crucial process whereby ...

Myriad Genetics stock plunges after UnitedHealth Group announces they will no longer cover genetic tests for mental health ...

As genetic testing becomes more available, patients are gaining unprecedented access to information about the likelihood of diseases and medical conditions. There is increased demand for professionals ...

The top genetic tests out right now are from Ancestry and the first in the business, 23andMe. Since they have come out there have been stories of financial struggles and data breaches at 23andMe ...